GNTAGenenta Science S.p.A.vs its industry peers
A metric-by-metric comparison of Genenta Science S.p.A. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GNTAEsta | $22M#7 | — | — | — | — | — | — | — | — | — | -62.9%#4 | — |
| ENTX | $542M#4 | 8.9x#1 | 74.6x#3 | 12903.2x#4 | -76.8%#4 | -19.9%#4 | -27450.0%#4 | -157.4%#2 | — | — | 10.6%#1 | — |
| EVAX | $1.2B#2 | — | — | 165.1x#3 | 125.1%#1 | 27.1%#2 | -122.7%#3 | — | — | — | -47.1%#3 | — |
| FENC | $362M#5 | — | 8.5x#2 | 8.1x#2 | -6.1%#3 | -2134.2%#5 | -14.1%#2 | -22951.3%#3 | -23.1%#2 | — | — | — |
| GPLB | — | — | — | — | — | -0.8%#3 | — | — | — | — | — | — |
| IMCR | $1.5B#1 | — | 3.6x#1 | 3.8x#1 | 29.0%#2 | 30.5%#1 | -11.3%#1 | -8.5%#1 | -12.1%#1 | — | — | — |
| IMTX | $924M#3 | — | — | — | — | — | — | — | — | — | -25.5%#2 | — |
| IPHA | $127M#6 | — | — | — | — | — | — | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-05.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice